SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotechnology Value Fund, L.P.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (1512)3/7/2000 9:18:00 AM
From: scaram(o)uche of 4974
 
biz.yahoo.com

(snip)

"It's the Celera effect," says Stefan Loran, analyst with Legg Mason Wood Walker in Baltimore who has no formal rating on
the stock. "Everyone and [his] brother is trying to go public."

"There's a real frenzy to raise money," adds Glyn O. Edwards, chief executive of Antisoma , a British biotechnology company
that listed on the London Stock Exchange last year. "They are trying to raise as much as they can to ride them out through the
rest of the cycle."

(snip)

It's so darn easy to call it the CRA effect. Whatever, it's here.

<g>
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News